We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$5.12B
1-Year Est. Return
314.02%
This Fund
S&P 500
This Quarter
Est. Return
+65.27%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$5.03B
AUM Growth
+$1.32B
(+36%)
Cap. Flow
-$125M
Cap. Flow
% of AUM
-2.48%
Top 10 Holdings %
Top 10 Hldgs %
53.64%
Holding
139
New
31
Increased
25
Reduced
19
Closed
25
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Korro Bio
KRRO
|
+$47.2M |
| 2 |
Agios Pharmaceuticals
AGIO
|
+$34M |
| 3 |
AnaptysBio
ANAB
|
+$23.6M |
| 4 |
QTNT
Quotient Limited Ordinary Shares
QTNT
|
+$20.7M |
| 5 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$20.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
|
+$104M |
| 2 |
Solid Biosciences
SLDB
|
+$69.8M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$46.8M |
| 4 |
Iovance Biotherapeutics
IOVA
|
+$36.4M |
| 5 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
+$33.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.17% |
| 2 | Financials | 0.38% |
| 3 | Technology | 0.12% |
| 4 | Consumer Discretionary | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GBT
1
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $466M | 9.26% |
5,865,726
-10,000
| -0.2% | -$593K |
|
|
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $413M | 8.2% |
3,203,406
-111,200
| -3% | -$10.7M |
|
|
3
Neurocrine Biosciences
NBIX
$18.2B
| $388M | 7.71% |
3,612,554
-447,346
| -11% | -$46.8M |
|
4
Kodiak Sciences
KOD
$2.53B
| $264M | 5.24% |
3,663,557
+528,358
| +17% | +$19.2M |
|
|
5
Iovance Biotherapeutics
IOVA
$2.04B
| $261M | 5.18% |
9,416,202
-1,598,500
| -15% | -$36.4M |
|
|
FOLD
6
DELISTED
Amicus Therapeutics
FOLD
| $245M | 4.86% |
25,132,364
+522,664
| +2% | +$4.78M |
|
|
ZGNX
7
DELISTED
Zogenix, Inc.
ZGNX
| $193M | 3.84% |
3,709,152
+445,000
| +14% | +$20.4M |
|
|
ATNX
8
DELISTED
Athenex, Inc. Common Stock
ATNX
| $176M | 3.5% |
576,623
+39,861
| +7% | +$10.5M |
|
|
AMRN
9
Amarin Corp
AMRN
$298M
| $152M | 3.03% |
355,304
-26,500
| -7% | -$10.1M |
|
10
BridgeBio Pharma
BBIO
$16.4B
| $142M | 2.83% |
6,706,268
| – | – |
|
11
MeiraGTx Holdings
MGTX
$1.08B
| $129M | 2.56% |
6,433,277
| – | – |
|
|
SWTX
12
DELISTED
SpringWorks Therapeutics
SWTX
| $128M | 2.55% |
3,337,522
+120,000
| +4% | +$2.81M |
|
|
QTNT
13
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $126M | 2.51% |
332,226
+62,500
| +23% | +$20.7M |
|
14
Zymeworks
ZYME
$1.62B
| $109M | 2.17% |
2,403,026
+14,136
| +0.6% | +$514K |
|
|
NVRO
15
DELISTED
NEVRO CORP.
NVRO
| $89.8M | 1.78% |
763,886
-210,887
| -22% | -$20.9M |
|
|
MYOK
16
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $87.9M | 1.75% |
1,206,411
+75,900
| +7% | +$4.6M |
|
|
KDMN
17
DELISTED
Kadmon Holdings, Inc.
KDMN
| $66.3M | 1.32% |
14,636,334
+1,470,588
| +11% | +$5.38M |
|
18
Crinetics Pharmaceuticals
CRNX
$8.88B
| $64.9M | 1.29% |
2,587,953
| – | – |
|
|
VBIV
19
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $63.4M | 1.26% |
1,531,719
| – | – |
|
|
MNTA
20
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $55.9M | 1.11% |
2,835,637
-69,363
| -2% | -$1.11M |
|
21
Verrica Pharmaceuticals
VRCA
$95.2M
| $52M | 1.03% |
341,041
| – | – |
|
22
Rocket Pharmaceuticals
RCKT
$342M
| $51M | 1.01% |
2,239,241
+261,829
| +13% | +$4.37M |
|
|
23
Korro Bio
KRRO
$146M
| $49.8M | 0.99% |
+60,686
| New | +$47.2M |
|
|
BPMC
24
DELISTED
Blueprint Medicines
BPMC
| $49.6M | 0.98% |
618,624
-264,640
| -30% | -$19.8M |
|
|
DBVT
25
DBV Technologies
DBVT
$821M
| $46.7M | 0.93% |
436,781
+75,873
| +21% | +$6.07M |
|
Similar funds
BG
TAM
CIA
AC
EIC
CIC
CS
NC
Perceptive Advisors's Q4 2019 Portfolio in Review
As of Q4 2019, Perceptive Advisors held 139 positions worth $5.03B, up 36% from $3.71B the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Perceptive Advisors's Q4 2019 filing shows 31 new, 25 increased, 19 reduced and 25 closed positions. Its largest new stake was Korro Bio: 60,686 shares worth $49.8M. The largest sale was Dova Pharmaceuticals, Inc. Common Stock, an estimated $104M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Financials and Technology.
- Perceptive Advisors's largest Q4 2019 buy was Korro Bio: 60,686 shares worth $49.8M.
- Perceptive Advisors added most to Quotient Limited Ordinary Shares in Q4 2019, an estimated $20.7M increase.
- Perceptive Advisors's biggest Q4 2019 reduction was Neurocrine Biosciences, cutting an estimated $46.8M.
- Perceptive Advisors fully exited Dova Pharmaceuticals, Inc. Common Stock in Q4 2019, selling an estimated $104M.
- Perceptive Advisors's ten largest holdings make up 54% of its $5.03B portfolio in Q4 2019.
- Perceptive Advisors opened 31 new positions and closed 25 in Q4 2019.
- Perceptive Advisors's portfolio value rose 36% quarter-over-quarter to $5.03B.
Based on Perceptive Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.